Innovative Fungal Diagnostic Receives FDA Recognition

Zepto Life Technology has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its FungiFlex Mold Panel, a diagnostic test designed to improve the detection and identification of invasive mold infections.

The designation marks a significant milestone for the Minnesota-based biotechnology company and highlights growing efforts to address the challenges associated with diagnosing life-threatening fungal diseases.

Invasive Mold Infections Remain a Major Healthcare Challenge

Invasive mold infections remain a major concern in healthcare, particularly among immunocompromised patients, including individuals undergoing cancer treatment, organ transplant recipients, and patients with weakened immune systems.

These infections can progress rapidly and are associated with high morbidity and mortality rates.

Early diagnosis is often critical for successful treatment, yet current diagnostic methods frequently struggle to provide timely and definitive organism identification.

The FungiFlex Mold Panel was developed to address these diagnostic limitations through the use of liquid biopsy technology.

Unlike conventional diagnostic approaches that may require invasive procedures or the integration of multiple testing methods, the FungiFlex assay analyzes fungal cell-free DNA (cfDNA) circulating within a patient’s plasma.

By examining a simple blood sample, the test aims to identify the specific fungal organism responsible for infection.

Giant Magnetoresistance Biosensor Technology

At the core of the technology is Zepto Life Technology’s proprietary Giant Magnetoresistance (GMR) biosensor platform.

The platform is designed to detect extremely small quantities of fungal genetic material released into the bloodstream during infection.

This approach allows clinicians to obtain organism-level information directly from plasma without requiring tissue biopsies or waiting for fungal cultures to grow.

According to the company, the assay is capable of detecting and identifying 14 clinically relevant mold pathogens.

These include major fungal groups responsible for invasive mold infections such as Aspergillus, Mucorales, Fusarium, and Scedosporium/Lomentospora.

Many of these pathogens are associated with severe disease and require different treatment strategies, making accurate species identification particularly important for patient management.

Major Mold Pathogens Detected by FungiFlex

Fungal Group	Associated Disease
Aspergillus	Aspergillosis
Mucorales	Mucormycosis
Fusarium	Fusariosis
Scedosporium	Scedosporiosis
Lomentospora	Opportunistic Infections

Generated by AI based on Zepto Life Technology FungiFlex specifications.

Limitations of Current Diagnostic Approaches

Current diagnostic pathways for invasive mold infections often involve a combination of radiological imaging, microbiological culture, histopathological examination, and serological testing.

While these methods can provide valuable information, they frequently present limitations.

Imaging findings may be nonspecific, cultures can take several days or weeks to produce results, and obtaining tissue samples may not always be feasible in critically ill patients.

Furthermore, organism-level identification remains difficult even when multiple diagnostic techniques are combined.

These challenges can result in delayed diagnosis or misdiagnosis, potentially leading to inappropriate treatment and poorer clinical outcomes.

Physicians are often required to make urgent treatment decisions before the causative pathogen has been definitively identified.

As a result, broad-spectrum antifungal therapies may be initiated empirically, which can increase costs, expose patients to unnecessary side effects, and contribute to antifungal resistance concerns.

Earlier Pathogen Identification May Improve Treatment

The FungiFlex Mold Panel seeks to overcome these obstacles by providing direct pathogen identification from plasma at the time invasive mold infection is suspected.

By identifying the causative organism earlier in the diagnostic process, clinicians may be able to select more targeted antifungal therapies and improve treatment outcomes.

Hannah Zhang, Chief Executive Officer of Zepto Life Technology, emphasized the clinical significance of obtaining organism-specific information during the early stages of infection.

She noted that one of the greatest challenges in managing invasive fungal diseases is the need to make critical treatment decisions without knowing the exact pathogen responsible for disease progression.

Traditional Diagnostics vs FungiFlex

Diagnostic Method	Limitation
Fungal Culture	Slow turnaround
Tissue Biopsy	Invasive
Imaging	Often nonspecific
Serology	Limited organism specificity
FungiFlex cfDNA Testing	Direct plasma-based pathogen identification

Generated by AI based on published fungal diagnostic workflows.

Understanding FDA Breakthrough Device Designation

The FDA’s Breakthrough Device Designation is intended to accelerate the development and review of medical technologies that may offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases.

Devices receiving this designation gain access to increased interaction with FDA experts and may benefit from a more efficient regulatory review process.

The designation reflects the agency’s recognition that invasive mold infections represent a serious unmet medical need and that innovative diagnostic approaches could play an important role in improving patient care.

While the designation does not constitute FDA clearance or approval, it signals the potential clinical value of the technology and supports its continued development.

The FungiFlex Mold Panel is currently available through Zepto Life Technology’s Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory as a laboratory-developed test (LDT).

This allows healthcare providers to access the assay while additional regulatory and clinical validation efforts continue.

Public Health Need for Better Fungal Diagnostics

The need for improved fungal diagnostics is supported by public health data.

According to the U.S. Centers for Disease Control and Prevention (CDC), invasive mold infections are frequently underdiagnosed or diagnosed late.

Such delays can contribute to severe illness, increased healthcare expenditures, prolonged hospitalization, and mortality.

The CDC estimates that the population-based prevalence of invasive mold infections in the United States ranges from approximately 15 to 18 cases per 100,000 individuals, though the burden is significantly higher among vulnerable patient populations.

Advances in molecular diagnostics have increasingly transformed the detection of infectious diseases over the past decade.

The application of cell-free DNA testing to fungal infections represents a growing area of research and clinical interest.

By leveraging circulating genetic material as a diagnostic target, liquid biopsy technologies offer the possibility of detecting infections earlier and with greater specificity than many traditional methods.

Precision Diagnostics May Transform Fungal Disease Detection

As healthcare systems continue to seek faster and more accurate approaches to infectious disease diagnosis, technologies such as the FungiFlex Mold Panel may contribute to a broader shift toward precision diagnostics.

The ability to rapidly identify invasive fungal pathogens from a blood sample could ultimately improve clinical decision-making, reduce diagnostic uncertainty, and enhance outcomes for patients facing some of the most dangerous fungal infections.

The FDA’s Breakthrough Device Designation therefore represents not only an important achievement for Zepto Life Technology but also a notable development in the ongoing effort to improve the diagnosis and management of invasive mold diseases.

Future clinical studies and regulatory evaluations will determine the full impact of this technology on fungal disease diagnostics and patient care.